Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naive or Treatment-Experiencedopen access
- Authors
- Lee, Hyun Woong; Yoo, Ki Young; Won, Joung Won; Kim, Hyung Joon
- Issue Date
- Sep-2017
- Publisher
- EDITORIAL OFFICE GUT & LIVER
- Keywords
- Hepatitis C; chronic; Sofosbuvir; Ledipasvir; Daclatasvir; Asunaprevir
- Citation
- GUT AND LIVER, v.11, no.5, pp 721 - 727
- Pages
- 7
- Journal Title
- GUT AND LIVER
- Volume
- 11
- Number
- 5
- Start Page
- 721
- End Page
- 727
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/3999
- DOI
- 10.5009/gnl17209
- ISSN
- 1976-2283
2005-1212
- Abstract
- Background/Aims: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. Methods: Patients (n=30) were enrolled between September 2015 and April 2016. Twenty-six patients were genotype 1 (1b, n=21; 1a, n=5) and four patients were genotype 2a/2b. Among 21 patients with genotype lb, Y93H resistance-associated variants (RAVs) were detected in three patients (14.3%). We evaluated sustained virologic response (SVRs) at 12 weeks, as well as relapse and safety. Results: Five patients with genotype la and three patients with genotype lb (RAV positive) received ledipasvir/sofosbuvir for 12 weeks. SVR12 rate was 100% (8/8). Eleven patients with genotype lb were treatment-naive and received daclatasvir plus asunaprevir for 24 weeks. SVR12 rate was 91% (10/11). One patient experienced viral breakthrough without RAV at 12 weeks. Seven treatment experienced patients with genotype lb received daclatasvir plus asunaprevir for 24 weeks. SVR12 rate was 85.7% (6/7). One patient experienced viral breakthrough with RAV (L31M, Y93H) at 12 weeks. Four patients with genotype 2a/2b received sofosbuvir plus ribavirin for 12 weeks. SVR12 rate was 100% (4/4). No serious adverse event-related discontinuations were noted. Conclusions: New direct acting antiviral treatment achieved high SVRs rates at 12 weeks in CHC patients with hemophilia without serious adverse events.
- Files in This Item
-
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.